Next Article in Journal
Virus–Host Cell Interactions
Next Article in Special Issue
Determination of WWOX Function in Modulating Cellular Pathways Activated by AP-2α and AP-2γ Transcription Factors in Bladder Cancer
Previous Article in Journal
IFN-γ Induces PD-L1 Expression in Primed Human Basophils
Previous Article in Special Issue
Angiogenesis Driven by the CEBPD–hsa-miR-429–VEGFA Signaling Axis Promotes Urothelial Carcinoma Progression
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cells
Volume 11
Issue 5
10.3390/cells11050803
cells-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside

by
Antonio Ungaro
1,
Marcello Tucci
2,
Alessandro Audisio
1,
Lavinia Di Prima
1,
Chiara Pisano
1,
Fabio Turco
1,
Marco Donatello Delcuratolo
1,
Massimo Di Maio
3,
Giorgio Vittorio Scagliotti
1 and
Consuelo Buttigliero
1,*
1
Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, 10124 Turin, Italy
2
Department of Medical Oncology, Cardinal Massaia Hospital, 14100 Asti, Italy
3
Department of Oncology, University of Turin, A.O. Ordine Mauriziano, 10124 Turin, Italy
*
Author to whom correspondence should be addressed.
Cells 2022, 11(5), 803; https://doi.org/10.3390/cells11050803
Submission received: 6 February 2022 / Revised: 22 February 2022 / Accepted: 23 February 2022 / Published: 25 February 2022
(This article belongs to the Special Issue Cell Biology in Urothelial Cancer)
Browse Figures
Review Reports Versions Notes

Abstract

Significant progress has been achieved over the last decades in understanding the biology and mechanisms of tumor progression in urothelial carcinoma (UC). Although the therapeutic landscape has dramatically changed in recent years with the introduction of immune checkpoint inhibitors, advanced UC is still associated with rapidly progressing disease and poor survival. The increasing knowledge of the pathogenesis and molecular pathways underlying cancer development and progression is leading the introduction of target therapies, such as the recently approved FGFR inhibitor Erdafitinib, or the anti-nectin 4 antibody drug-conjugate Enfortumab vedotin. Antibody drug conjugates represent an innovative therapeutic approach that allows the combination of a tar get-specific monoclonal antibody covalently conjugated via a linker to a cytotoxic agent (payload). UC is a perfect candidate for this therapeutic approach since it is particularly enriched in antigen expression on its surface and each specific antigen can represent a potential therapeutic target. In this review we summarize the mechanism of action of ADCs, their applications in localized and metastatic UC, the main mechanisms of resistance, and future perspectives for their use in clinical practice.
Keywords: urothelial carcinoma; antibody-drug conjugates; ADC; Enfortumab vedotin; ADC resistance mechanism urothelial carcinoma; antibody-drug conjugates; ADC; Enfortumab vedotin; ADC resistance mechanism

Share and Cite

MDPI and ACS Style

Ungaro, A.; Tucci, M.; Audisio, A.; Di Prima, L.; Pisano, C.; Turco, F.; Delcuratolo, M.D.; Di Maio, M.; Scagliotti, G.V.; Buttigliero, C. Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside. Cells 2022, 11, 803. https://doi.org/10.3390/cells11050803

AMA Style

Ungaro A, Tucci M, Audisio A, Di Prima L, Pisano C, Turco F, Delcuratolo MD, Di Maio M, Scagliotti GV, Buttigliero C. Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside. Cells. 2022; 11(5):803. https://doi.org/10.3390/cells11050803

Chicago/Turabian Style

Ungaro, Antonio, Marcello Tucci, Alessandro Audisio, Lavinia Di Prima, Chiara Pisano, Fabio Turco, Marco Donatello Delcuratolo, Massimo Di Maio, Giorgio Vittorio Scagliotti, and Consuelo Buttigliero. 2022. "Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside" Cells 11, no. 5: 803. https://doi.org/10.3390/cells11050803

APA Style

Ungaro, A., Tucci, M., Audisio, A., Di Prima, L., Pisano, C., Turco, F., Delcuratolo, M. D., Di Maio, M., Scagliotti, G. V., & Buttigliero, C. (2022). Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside. Cells, 11(5), 803. https://doi.org/10.3390/cells11050803

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop